Navigation Links
Big Pharma Dealmaking Activity Highlighted by CurrentPartnering in Comprehensive Report Published at

London, UK (PRWEB) September 09, 2013

What are the leading big pharma companies? What does the company’s recent dealmaking activity look like? What are the key terms included in a partnering agreement? What are the key aspects of partnering? What are the predominant big pharma companies’ dealmaking trends over the last four years? How to assess a prospective partner’s flexibility? How to submit an opportunity to big pharma? How to determine under what terms a prospective partner agrees to a partnering relationship? How does the negotiation process look like? What are the key issues and aspects of the dealmaking? What is actually granted by the agreement to the partner company? How are disputes during the dealmaking process resolved? Which jurisdiction does the company insist upon for agreement law? The answers to all these questions and other essential information required to better understand big pharma partnering ?an be found in the report.

Comprehensive research report “Partnering Deals and Alliances with Big Pharma” worked out by CurrentPartnering has been recently published by Market Publishers Ltd.

Report Details:

Title: Partnering Deals and Alliances with Big Pharma
Published: July, 2013
Pages: 877
Price: US$ 2,995.00

The report offers in-depth insights into the dealmaking interests and activity of the world’s top fifty big pharma companies by providing their comprehensive partnering activity profiles. It presents essential data on each of the companies’ partnering activities since 2007; presents a full listing of partnering deals by deal type, industry sector, phase of development, technology type and therapeutic area; grants comprehensive access to over 3,000 partnering deals together with contract documents if available. The research contains gives objective insights into the terms included in a partnering agreement, with real world clause examples; uncovers details on the forthcoming big pharma partnering events, and evaluates the big pharma future opportunities.

Reasons to Buy:

  • The report provides a reader with an in-depth understanding of the partnering activities of the leading fifty big pharma companies worldwide.
  • Comprehensive dealmaking profiles of the companies enable to understand the key aspects of the partnering deals and to prepare for making a successful contract.
  • The study helps to undertake the key deal terms as well as due diligence to assess suitability of proposed deal terms for partner companies.
  • Review of the company’s dealmaking activity during 2007-2013 assist in assessing and choosing the potential business partners.

More in-demand research studies by CurrentPartnering can be found at

About Us: is a multilingual hypermarket offering a rich collection of comprehensive studies on various markets, sectors, industries, companies, etc. We perform professional services aimed to equip our clients with high-quality research products and support critical decision-making.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lawsuit Alleges Takeda Pharmaceutical Co., Maker of Diabetes Drug Actos, Didn’t Warn of the Drug’s Risks Soon Enough; Parker Waichman LLP Responds
2. Targeted Medical Pharma Initiates Clinical Trial of Red Blood Cell Stimulating Formulation
3. Global Pharmaceutical Packaging Market is Expected to Reach USD 73.04 Billion in 2018: Transparency Market Research
4. 67 Pharmaceutical Markets with 2013 Facts & Figures Reviewed in New Research Report at
5. Pathways Pharmacist Denise Schoenberger Honored for Healthcare Excellence by Silicon Valley Business Journal
6. Drug Delivery Technology Pharmaceutical Market (Metered Dose Inhalers, Needle-Free Injectors) is Worth $224.2 Billion by 2017 - New Report by MarketsandMarkets
7. Leiter's Compounding Pharmacy Welcomes New Director of Marketing
8. World Radiopharmaceuticals Market to Reach USD 5.5bn in 2017, According to M&M Report Available at
9. Phen375 Released The Newest Pharmacy-Grade Rapid Weight Loss Supplement
10. Could You Have Sleep Apnea? - Consumer Wellness Tips from Ritch's Pharmacy and HealthMart
11. Pharmaceutical Excipients Market Demand was 519.5 Kilo Tons in 2011 And is Expected to Reach 685.6 Kilo Tons in 2018 : Transparency Market Research
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 10, ... States District Court of Connecticut on behalf of a home health care worker who ... current or former home health care workers employed by Humana, Inc., Humana at Home, ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
(Date:11/25/2015)... ... , ... SCOTTSDALE, AZ) - Today, Dr. Todd C. ... and non-surgical treatments, announced the expansion of his private practice capabilities with the ... Highly trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Today, ... on our nation’s roadways has dropped below 10,000 for the first time since 2011. ... in 2013. , According to data released by the National Highway Traffic Safety Administration ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 25, 2015 ... due to repeated failure of IVF cycles. After failure ... was totally dejected and had lost all hopes that she would be able ... Indian miracle child conceived after failure of over 15 ... abroad (UK) before they decided to take one last attempt with ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
(Date:11/24/2015)... /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") ... the first patient has been enrolled in ESSA,s Phase ... metastatic castration-resistant prostate cancer ("mCRPC"). the ... the United States and Canada.  ... trial, ESSA intends to demonstrate the safety, tolerability, maximum ...
Breaking Medicine Technology: